Introduction: HIV-tuberculosis (TB) co-infection remains an important cause of mortality in sub-Saharan Africa. Clinical trials have reported early (within 2 weeks of TB therapy) antiretroviral therapy (ART) reduces mortality among HIV-TB co-infected research participants with low CD4 þ cell counts, but this has not been consistently observed. We aimed to evaluate the current WHO recommendations for ART in HIV-TB co-infected patients on mortality in routine clinical settings.
Introduction
HIV-tuberculosis (TB) co-infection remains a leading cause of mortality in sub-Saharan Africa despite increasing availability of antiretroviral therapy (ART) [1] . Randomized trials have [2] reported a reduction in mortality or incidence of AIDS-defining illness among HIV-TB co-infected research participants with low CD4 þ cell counts who start ART within 2 weeks of TBtreatment initiation [3] [4] [5] . As a result, the WHO guidelines have been revised [6] to recommend early ART, particularly in HIV-TB co-infected patients with CD4
þ cell counts less than 50 cells/ml [2, 7, 8] . A few observational studies, most of which are retrospective, demonstrate this beneficial effect of ARTon outcomes of HIV-TB co-infected patients with low CD4 þ cell counts [9] [10] [11] [12] , whereas other randomized studies have shown limited or no benefit of early versus delayed ART initiation [13] [14] [15] . Additional observational studies are important as concurrent HIV-TB treatment is associated with high risk of complications like tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS), drug toxicities, and unmasking of other opportunistic infections, which may further influence clinical outcomes. Some of these complications may justify delayed start of ART in selected HIV-TB co-infected patients who are at high risk of poor outcomes.
Most randomized studies have compared mortality outcomes of two distinct HIV-TB co-infected populations starting ART early (<2 weeks) or late (>8 weeks) after initiation of TB treatment. Few studies have reported the outcomes for patients who start ART between 2 and 8 weeks after the start of TB treatment [3] [4] [5] .
We aimed to evaluate the effect of starting ART early (2 AE 1 week) versus starting ART late (!3 weeks) after starting TB treatment on mortality outcomes of HIV-TB co-infected participants.
Methods
We examined the effect of early versus delayed ART on mortality from two prospective cohort studies in a high burden HIV-TB setting before [16, 17] and after the WHO guideline change on timing of ART initiation. The delayed ART initiation cohort run from 7 January 2008 to 30 July 2010 at the Mulago TB Treatment Centre whereas the early ART initiation cohort involved participants attending the HIV-TB clinic of Infectious Disease Institute within the same Mulago Hospital Complex from 13 January 2012 to 17 December 2013. The studies were conducted by the same clinical team that used similar case definitions for TB diagnosis and for classification of study outcomes. Study participants were enrolled from the Mulago HIV-TB clinic and the Infectious Disease Institute, HIV-TB  clinic in Kampala, Uganda. The inclusion criteria for  enrolment were: HIV-TB co-infected, ART-naive  adults who were 18 years or older with CD4 þ cell counts 100 cells/ml or less and were willing to participate in the study. Participants who had elevated liver transaminases greater than five times or were unable to return for study visits were excluded from the study.
Participant enrolment and study procedures
History and physical examination were done for all participants who consented to participate in the study. The age (years), sex, weight, and height were determined and BMI was calculated (kg/m 2 ). Investigations to confirm the diagnosis of TB and HIV were done. All participants had sputum examination for acid fast bacilli (AFB), a chest Xray, and abdominal ultrasound scan performed. TB was diagnosed as bacteriologically positive if they were AFB sputum smear-positive, had a positive Lowenstein-Jensen culture (or Mycobacterium Growth Inhibition Tube (MGIT) technique in the early ART cohort, or Mycobacterium tuberculosis detected on Xpert MTB/RIF (Cepheid, Sunnyvale, California, USA); the Xpert MTB/RIF technology was available only at the time of the 2012-2013 cohort. TB was confirmed by a positive result on microscopy, Xpert or culture; and extrapulmonary TB was diagnosed according to criteria recommended by WHO [18] . A diagnosis of Kaposi's sarcoma was made on histological examination of biopsies of suspected skin lesions. Cryptococcal meningitis was diagnosed during hospitalization in patients who had suggestive clinical symptoms and had lumbar punctures and cerebral spinal fluid positive for Cryptococcus spp.
Haemoglobin level (g/dl) was determined at baseline (ART start) and the participants were classified according to WHO clinical staging. Serum cryptococcal antigen (CrAg) test was also performed at enrolment among asymptomatic participants. CrAg testing was by latex agglutination in 2008-2010, and by lateral flow assay (Immy Inc, Norman, Oklahoma, USA) in 2012-2013. Participants with a positive serum CrAg were treated with fluconazole (400 mg once daily in the delayed ART cohort and 800 mg in the early ART cohort -consistent with revised WHO guidelines for preemptive treatment for HIV persons with a positive serum CrAg) [19] .
TB treatment was provided using standard treatment regimens recommended by the National Tuberculosis Programme, which included ethambutol (E), Isoniazid (H), rifampicin (R), and pyrazinamide (Z) for the intensive phase of 2 months followed by either 4 months of RH or 6 months of EH.
Antiretroviral therapy
In the delayed ART cohort 2008-2010, ARTwas started at least 3 weeks after starting TB treatment whereas in the early ART cohort 2012-2013, ART was started 2 AE 1 weeks after starting TB treatment in participants with CD4 þ cell counts less than 100 cells/ml. In both periods, ART in TB patients consisted of triple therapy: a backbone of two nucleoside reverse transcriptase inhibitors (zidovudine or stavudine with lamivudine) with a nonnucleoside reverse transcriptase inhibitor (efavirenz or nevirapine).
Follow-up Participants were followed up at week 2, months 1, 3, 6 following ART initiation; and at TB treatment completion. Participants were encouraged to come for a sick (unscheduled) clinic visit if they developed any worsening of symptoms during follow-up. The participants were evaluated during follow-up for any treatment-related complications like drug toxicities, new opportunistic diseases or TB-IRIS. Participants who did not return for a follow-up visit were traced using locator information and contacts they provided to establish their vital status.
Study outcomes
The main study outcome was mortality during follow-up. Mortality data were either obtained from hospital or postmortem records if participants were hospitalized prior to death or from the relatives or close associates who were identified as the next of kin. Participants were censored when they left the study or when they completed TB therapy. Participants who developed TB-IRIS were evaluated with a standard questionnaire and investigations for a final diagnosis of definite/probable TB-IRIS or not TB-IRIS; adjudication was made by clinician consensus based on the above findings. Participants who developed cryptococcal meningitis were hospitalized and treated for 2 weeks with daily amphotericin infusion (1 mg/kg) followed by fluconazole maintenance therapy.
Statistical analysis
Delayed ART initiation was defined as ART initiation at least 3 weeks after TB treatment initiation, and early ART initiation was defined as ART initiation within 2 weeks (AE1 week) of TB treatment initiation.
The primary analysis evaluated the effect of early versus delayed ART initiation on mortality comparing survival time from the date of starting TB treatment to either death, loss to follow-up or administrative censoring at the end of TB therapy. As survival time was calculated from TB treatment initiation, deaths occurring before ART initiation were attributed to the respective ART initiation strategy for complete measure of the total mortality that would accrue from the respective ART initiation strategy.
Secondary analyses compared the effect of early versus delayed ART initiation on mortality in sub-populations of participants with baseline CD4 þ cell counts less than 50 and 50-100 cells/ml, adjusted for age, sex, hemoglobin level, TB category (extrapulmonary or not), and serum CrAg status. We also compared mortality among patients with positive and negative CrAg tests.
In sensitivity analysis, we evaluated the effect of potential contamination between the two study arms by allowing a short wash-out effect (from day 15 to day 21) to preserve more statistical power in the study or a longer wash-out effect (from day 15 to day 49) comparable with the randomized clinical trials [4, 5, 13] , by restricting the Early ART cohort to 2 weeks or less of ART initiation; and by restricting the delayed ART cohort to more than 3 weeks and more than 7 weeks, respectively.
In order to allow for precise estimation of the effect of timing of ART initiation on the mortality of the TB-HIV participants, we used inverse-probability censoringweighted Cox models with robust sandwich variance estimates to balance the study population in the delayed and early arm for baseline characteristics, probability of censoring and survival time. 
Results

Study participants
Of 387 participants with HIV-TB co-infection, who initiated TB medication with baseline CD4 þ cell counts 100 cells/ml or less, 201 were in the delayed ART cohort and 186 in the early ART cohort. In the delayed ART cohort, 21 participants were excluded from the analysis, including 6 missing baseline CrAg results and 15 initiated on ART within 3 weeks of starting TB medication, whereas in the early ART cohort, 10 were excluded from the analysis, including, 2 participants missing the hemoglobin results, 2 missing their baseline CrAg results and 6 initiated on ART after 3 weeks of starting TB medication. Therefore, 356 participants were included in the analysis, including 180 in the delayed ART cohort and 176 in the early ART cohort (Fig. 1 ). Overall 311 (87%) study participants started ART. Reasons for failure to start ART included death 17 (38%), study withdrawal 7 (15%), moving away from study area 6 (13%), loss to follow-up 4 (9%), interrupting ART or TB treatment or failure to keep study appointments 4 (9%); deferring ARTuntil completion of TB treatment 4 (9%) or taking ART from another site 3 (7%).
The median age of study participants was similar, 32.5 years (IQR 27-39) and 32 years (IQR 28-38) in the delayed ART cohort and early ART cohort, respectively. Women constituted 47 and 48% in the delayed ART cohort and early ART cohort, respectively. Participants' median baseline CD4 þ cell counts was 26.5 cells/ml (IQR 11-52) and 26 cells/ml (IQR 11-48) in the delayed ART cohort and early ART cohort, respectively. Of the participants who started ART 288 (92.6%) had complete ART regimen information. In the Delayed ART cohort, majority of study participants were on stavudine 49 (35.3%) and zidovudine-based 85 (61.2%) regimens, whereas in the early ART cohort, majority of the study participants were on tenofovir-based regimens 154 (96.9%). At bivariate analysis WHO-staging IV (P < 0.001), having extra-pulmonary TB (P < 0.001), hemoglobin less than 8.0 g/dl (P ¼ 0.008), and a positive CrAg test (P ¼ 0.002) were significantly associated with early ART cohort assignment (Table 1 the two cohorts were more evenly distributed on the respective confounders (Table 1) .
Mortality in HIV-tuberculosis
A total of 69 (19.4%) participants died during the study. In the delayed ARTarm, mortality was 18.3% (33/180) with 5.5% (10/180) mortality before starting ART and 12.8% (23/180) after starting ART. In the early ART arm, mortality was 21.6% (38/176); with 4.0% (7/176) mortality before starting ART and 17.6% (31/176) after starting ART (Fig. 1) . Overall, the median time of death was 74 (IQR 42-147) days after starting TB treatment. The overall crude mortality incidence among all participants was 28.4 per 100 person-years (95% CI 21.3-38.6; Table 2 ) with 25.2 per 100 person-years (95% CI 16-41.9) and 32.6 per 100 person-years (95% CI 22.9-47.6) in the delayed ART and early ART cohorts, respectively.
Causes of death
Thirty-nine (57%) of the 69 study participants who died had a documented cause of death from hospitalization or postmortem records. The identified causes of death in the delayed ART cohort included gastroenteritis with severe
, and renal failure (n ¼ 1). In the early ART cohort, the causes of death were cryptococcal meningitis (n ¼ 6), Kaposi's sarcoma (n ¼ 2), drug-induced liver toxicity (n ¼ 2), pulmonary embolism (n ¼ 2), pneumocystis pneumonia (n ¼ 1), TB-IRIS (n ¼ 1) and sepsis (n ¼ 1).
TB-IRIS occurred in 68 (19%) of the study participants. Majority of the TB-IRIS cases 45 (66%) occurred in the delayed ART cohort and TB-IRIS was not predictive of mortality. Four of the six participants who died of cryptococcal meningitis in the early ART cohort had unmasking cryptococcal meningitis. ART initiation. There was an increased risk of death in participants with a positive CrAg antigen test who received both delayed ART (aHR ¼ 4.17, 95% CI 1.9-9.0; P < 0.001) and early ART (aHR ¼ 2.63, 95% CI 1.0-6.8; P ¼ 0.045) compared with participants who had a negative CrAg test who received delayed ART (Table 2) . When we restricted the analysis to participants with baseline CD4 þ cell counts 50 cells/ml or less and a negative CrAg test, we still found a marginally significant increased risk of death in participants who initiated ART early compared with those who received delayed ART (aHR ¼ 1.95, 95% CI 1.0-3.9; P ¼ 0.054). Compared with participants who were CrAg negative in the delayed ART cohort, there was a five times increased risk of death in participants who had a positive CrAg test who received delayed ART (aHR ¼ 4.78, 95% CI 2.2-10.5; P < 0.001) and a marginally significant increased risk of death in participants with a positive CrAg test who received early ART (aHR ¼ 2.78, 95% CI 1.0-7.9; P ¼ 0.053). When we restricted the analysis to participants with baseline CD4 þ cell counts 51-100 cells/ml, there were no significant differences in any of the strata (supplementary material, Table 1s , http://links.lww.com/QAD/B320). In the sensitivity analysis, we found no significant differences in outcomes with or without the wash-out effect of 2-3 weeks or 2-7 weeks (supplementary material, Table 2s  and Table 3s , http://links.lww.com/QAD/B320).
Predictors of mortality
Age greater than 25 years was associated with decreased risk of death; for participants aged 25-34 years (aHR ¼ 0.30, 95% CI 0.1-0.6; P < 0.001) and for participants aged 35-44 years (aHR ¼ 0.39, 95% CI 0.2-0.7; P ¼ 0.03) ( Table 2 ). Restricting to participants with CD4 þ cell count 50 cells/ml or less, we observed a similar association comparing participants aged 18-24 years old to participants aged 25-34 years (aHR ¼ 0.21, 95% CI 0.1-0.5; P < 0.001), and participants aged 35-44 years (aHR ¼ 0.32, 95% CI 0.2-0.6; P ¼ 0.001). Similarly, WHO stage IV (aHR ¼ 1.92, 95% CI 1.2-3.3; P < 0.017) remained predictive of mortality and CrAg-positive result remained a significant effect modifier for the effect of timing of ART initiation (Table 3) .
Discussion
Starting ART among HIV-TB co-infected patients during TB treatment is crucial as it has been associated with reduced mortality [3] [4] [5] 14] . This reduction in mortality, especially among patients with CD4 þ cell counts less than 50 cells/ml has been confirmed in clinical trials and systematic reviews [4, 8] . On the basis of this evidence, WHO has recommended that ART should be 2146 AIDS 2018, Vol 32 No 15 Delayed, ART initiation delayed beyond 21 days; early, ART initiation within 21 days. Results presented are weighted using stabilized inverse probability weights. ART, antiretroviral therapy; CI, confidence interval; CrAg -P, positive cryptococcal antigen test; CrAg-N, negative cryptococcal antigen test; HR, hazard ratio; TB-IRIS, tuberculosis immune reconstitution inflammatory syndrome.
a Extrapulmonary TB is collinear with WHO staging, so it is excluded from the multivariate analysis started as an emergency in HIV-TB co-infected patients within 2 weeks of TB treatment initiation in patients with CD4 þ cell counts less than 50 cells/ml [20] .
In this observational study, we saw no difference in mortality among participants with CD4 þ cell counts 50 cells/ml or less who were started on early versus delayed ART. We found a significant increase in mortality rates in participants with asymptomatic cryptococcal antigenemia in both early and delayed ART study arms. Our study findings corroborate those reported by Amogne et al. [13] and Manosuthi et al. [14] , which did not show a reduction in mortality despite early ART initiation and indicated the role of comorbidities in diluting the treatment effect particularly in sub-Saharan Africa. Early ART has also not been shown to reduce mortality in participants with other categories of TB, like TB meningitis as observed by Torok et al. [21] . For participants with CD4 þ cell counts 50-100 cells/ml, we found no difference in mortality between the early and delayed ART groups. This is similar to what was reported in the clinical trials [3, 5] . Mfinanga et al. [22] found no benefit of early ART in patients with CD4
þ cell counts greater than 220 cells/ml and suggested that ART initiation in HIV-TB co-infected patients with high CD4 þ cell counts could be deferred until TB treatment is completed.
There are important differences between the studies on ART initiation in HIV-TB co-infected persons (Table 4) . First, the patient populations studied had varied levels of median CD4 þ cell counts. Our study participants had severe CD4 þ cell counts depletion (median CD4 þ of 24 cells/ml) comparable with the trial population of Blanc et al. [4] (median CD4 þ of 25 cells/ml). Most other studies had participants with higher CD4 þ cell counts and, in those studies, the effect of early ARTon mortality in HIV-TB co-infected persons was less prominent. Second, the difference in prevalence and management of opportunistic infections may influence the final patient outcomes. For instance, despite having low CD4 þ cell counts, the CAMELIA study in Cambodia [4] had fewer deaths attributable to cryptococcal meningitis (2 out of 149) and KS (0 out of 149) compared with our study. Third, our study mainly focused on the primary outcome of mortality whereas some studies used a composite outcome of mortality and AIDS-defining illnesses. Fourth, there is a wide variation in the difference in the time to ART initiation in different studies. Most studies compared early ART (<2 weeks of TB treatment start) with delayed ART start (>8 weeks after TB treatment). In our study, ARTwas started relatively early after TB treatment in both cohorts (median 14 days in the early ART cohort versus 44 days in the delayed ART cohort).
An important difference between the two HIV-TB cohorts studies analyzed was the difference in ART regimens used. There was a country-wide change in the recommended NRTI backbone from a stavudine and zidovudine-based regimen (in the delayed ART cohort) to a tenofovir-based ARTregimen (in the early ART cohort). Several studies and a Cochrane review have demonstrated that using a tenofovir-based regimen leads to superior viral suppression, immunological response and tolerability than a zidovudine or stavudine-based regimen [23] [24] [25] . As a result, we may have understimated the mortality attributable to ART in the early ART cohort.
Our results indicate that positive serum CrAg, an independent predictor of mortality in HIV-TB coinfected patients has been reported previously in patients with HIV starting ART [26] [27] [28] and in HIV-TB cohorts [16] . Early identification of patients with cryptococcosis and preemptive treatment with fluconazole is costeffective and may curb the excess mortality from cryptococcal disease [29, 30] . We also note that some of the participants in the Early ART cohort 'unmasked' cryptococcal meningitis despite having had a negative Early mortality in HIV-tuberculosis therapy Worodria et al. 2147 serum CrAg at study enrolment when starting TB therapy. These may represent missed diagnoses of subclinical cryptococcal antigenaemia in patients with advanced HIV immune suppression. Additional screening for cryptococcosis during the initial months of ART in patients with low CD4 þ cell counts may identify participants with cryptococcal antigenaemia who may benefit from fluconazole or amphotericin treatment. The low incidence of cryptococcal meningitis in the study by Blanc et al. [4] could be attributed to routine use of prophylactic fluconazole unlike in our study where it was only provided to participants with a positive serum CrAg at baseline. Lastly, the optimal time to ART initiation among patients with cryptococcal antigenaemia has not been established. In the trial by Boulware et al. [31] , early ART was associated with increased mortality in patients with cryptococcal meningitis. The known benefits of early ART in TB patients with CD4
þ cell counts less than 50 cells/ml seen in other studies may have been counteracted by the negative effects of early ART on patients with cryptococcal infection.
We also observed at least 10 per 100 person-years higher rates of mortality in our study compared with the randomized trials. Not surprisingly, WHO stage IV disease was also independently associated with increased mortality. This suggests that our study population may have had more advanced HIV diseases with more opportunistic infections and comorbidities leading to increased mortality. This in turn undercut the benefit of early ART initiation in patients with CD4
þ cell counts 50 cells/ml or less. There was a higher mortality among young adults aged 18-24 years co-infected with HIV-TB compared with older age groups. This may be because of delayed access to HIV and TB services by the young adults as a result of stigma and discrimination, nondisclosure and the lack of youth-friendly services in the public health sector. This has been reported in the context of challenges in access and adherence to ART [32] .
Our study had some strengths and weaknesses. The study compared two well characterized HIV-TB cohorts designed to study predictors of mortality. As observational studies, they were closer to a real-life situation. However, one cannot exclude bias in patient selection resulting in significant differences in the baseline populations (Table  1) . We used inverse-probability censoring-weighted Cox models to address these baseline discrepancies. However, there could still be unmeasured confounders that could have led to poor model specification in generating the weights. It is also important to note that our results may only be generalizable to similar low income settings with a high burden of HIV-TB co-infection and opportunistic diseases like cryptococcal meningitis.
Conclusion
Early ART in patients with HIV-TB co-infection was not associated with reduced risk of mortality in these real world observational cohorts. Cryptococcal antigenaemia in severely immunosuppressed AIDS patients with HIV-TB patients is associated with increased mortality in both early and delayed ART.
